Previous Pause Next
Home >> Resource Center >>
Patent
DNA synthesis PDF Print E-mail
Monday, 23 March 2009 08:54
Patent numberDescriptionAssigneeInventorPriority application datePublication date

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://www.thomson.com/scientific).

WO 2007117331, WO 2007117331

A new DNA polymerase from Thermoanaerobacter tengcongensis having a specific amino acid sequence; useful for procedures requiring strand-displacing DNA synthesis and for reverse transcription.

 

GE Healthcare Biosciences (Piscataway, NJ, USA)Fuller CW, Hamilton S, Sundaram S12/22/200510/18/2007, 5/22/2008
WO 2008044339

A DNA synthesis inhibitor in retinal vascular endothelial cells for treating age-related macular degeneration, vitreous hemorrhage, macular edema, premature retinopathy or uveitis; contains fat-soluble statin or its salt or solvate.

 

Aqumen Biophamaceuticals (Fukuoka City, Japan), Kyushu University (Fukuoka City, Japan)HataY, Ishibashi T, Iwaki H, Kagimoto T10/13/20064/17/2008
WO 2007059330, WO 2007059330

New cubane nucleoside analog compounds that are viral DNA synthesis inhibitors; useful for treating viral infection, for example, hepatitis B, hepatitis C, HIV-1, herpes simplex viruses (HSV)-1, HSV-2, Epstein-Barr viral infection and cancer.

 

Medkura (Fairfield, NJ, USA)Murphy RB, Trampota M11/17/20055/24/2007, 12/21/2007
US 2007026469

A method for generating a DNA molecule by coupling the hybridized oligonucleotides comprising at least one nonnatural nucleotide to form a first nucleotide strand and synthesizing a first complement to the first nucleotide strand.

 

EraGen Biosciences (Madison, WI, USA)Prudent JR4/7/200611/15/2007
WO 2007130967

A new oligonucleotide primer comprising a 5' universal sequence, a 3' target-specific primer sequence or an extension sequence; useful for initiating polymerase-catalyzed DNA synthesis at a target region on a polynucleotide template.

 

Siemens Medical Solutions Diagnostics (Tarrytown, NY, USA)Reynolds R5/1/200611/15/2007
WO 2007076461

A new thermostable DNA polymerase from Thermus scotoductus having a specific amino acid sequence; useful for procedures requiring strand-displacing DNA synthesis, for DNA sequencing, reverse transcription and PCR.

 

GE Healthcare Biosciences (Piscataway, NJ, USA)Fuller CW, Hamilton S, Rech R12/22/20057/5/2007
EP 1780289, JP 2007116999, US 20070141595

A method for assaying Regenerating islet–derived family, member 4 (regenerating gene type 4) mRNA comprising using a primer and using the RNA transcript in turn as a template for DNA synthesis to amplify the RNA transcript in a chain-reaction.

 

Tosoh (Yamaguchi, Japan)Hayashi T, Saito J, Une K10/28/20055/2/2007, 5/17/2007, 6/21/2007
US 20070134677, WO 2007070270

Forming a biochemical molecule such as DNA, comprising exposing a substrate prepared for light-directed synthesis of abiochemical molecule to light to define active and inactive regions and disabling synthesis in the inactive region.

 

Wisconsin Alumni Research Foundation (Madison, WI, USA)Cerrina F, Kim C12/9/20056/14/2007, 6/21/2007
US 20070128656

A method of incorporating a fluorescent label during first-strand complementary DNA synthesis, comprising providing a primer with a fluorescent label attached to one end.

 

University of South Florida (Tampa, FL, USA)Agrawal D, Gross WW6/26/20036/7/2007
WO 2007035489, AU 2006292482

A method of inhibiting DNA synthesis and DNA repair in a cell, comprising providing a 2-carboxyaldehyde pyridine thiosemicarbazone compound, contacting the cell with the compound and exposing the cell to ionizing radiation.

 

US Dept. of Health and Human Services (Washington, DC, USA)Camphausen K, Gius D, Tofilon P9/16/20053/29/2007, 3/29/2007
WO 2006006079, EP 1734985

Inhibiting DNA synthesis, p44/p42 mitogen-activated protein kinase activation or tube formation in arterial endothelial cells, comprising contacting the arterial endothelial cells with ephrinB2.

 

Aqumen Biopharmaceuticals (Fukuoka City, Japan)Fujisawa K, Hata Y, Ishibashi T, Kagimoto T4/5/20041/19/2006, 12/27/2006
WO 2005111209, JP 2005328709

Performing high-speed PCR useful for gene expression analysis, involving carrying out PCR under a specific temperature change, using heat-resistant Thermococcus kodakaraensis DNA polymerase exhibiting higher speed for DNA synthesis.

 

Toyo Boseki (Osaka, Japan)Nakajima T, Oka M, Segawa M5/18/200411/24/2005, 12/2/2005
 
Tissue Culture PDF Print E-mail
Monday, 23 March 2009 08:52
Patent numberDescriptionAssigneeInventorPriorityapplication datePublication date

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://www.thomson.com/scientific).

GB 2445213,
DE 102007054065,
US 20080160615,
JP 2008161184

In vitro flavonoid-rich tissue from Neomarica gracilis having antitumor activity, obtained from a tissue culture preparation, which alters flavonoid content of N. gracilis, where flavonoids-rich tissue comprises tectorigenin; useful as a cytostatic, antibacterial and/or fungicide.

 

Tatung Co.,
Tatung University,
Tatung Holdings Co. (Taipei, Taiwan)
Chu T, Ho C12/29/20067/2/2008,
7/3/2008,
7/3/2008,
7/17/2008
US 20080160560

A new in vitro resveratrol-rich callus tissue derived from Vitis thunbergii Sieb. et Zucc. induced in a tissue culture system containing one or more plant growth regulators; useful for callus induction and producing resveratrol.

 

Ho C, Kuo HHo C, Kuo H1/3/20077/3/2008
WO 2008073331,
US 20080152630

A method for generating and expanding tissue-progenitor cells or mature tissue cells in culture,comprising culturing intact bone marrow or intact umbilical cord tissue in a cell differentiation medium.

 

Ginis I, Schwartz A, Shinar D, Shirvan M, Teva Pharmaceuticals (Petah Tikva, Israel and North Wales,PA, USA)Ginis I,Schwartz A,Shinar D,Shirvan M12/7/20066/19/2008,
6/26/2008
EP 1930411,
WO 2008068776

A method of preparing a three-dimensional tissue equivalent comprising a cellular sheet of cells,comprising culturing cells onto the surface of the porous scaffold or matrix; useful for therapy such as treating or dressing a wound.

 

Reliance Life Science (Mumbai)Deshpande MS, Kuchroo PV, Manisha SD, Pralhad BW,Pushpa VK,Rao SH,Sitahmraju HR, Wangikar PB12/8/20066/11/2008,
6/12/2008
JP 2008106064

An enhancer of tissue plasminogen activatorproduced by heat processing Bacillus natto culture solution; useful as a pharmaceutical or foodstuff for preventing thrombotic diseases.

 

Honda Trading KK (Tokyo), Sumi YSumi Y9/28/20065/8/2008
JP 2008086509

A composition for regenerating periodontal-tissue(e.g., gum) comprising a culture medium having acell suspension of human periodontal membranepositioned on the upper region and a chemotaxissubstance blended on the lower region of the medium.

 

Sun Medical KK (Morioka, Japan)Munakata M, Tajima K, Tsuchiya Y9/29/20064/17/2008
CN 101152580

A tissue-engineered skin manufacturing methodinvolving obtaining skin tissue, confecting anepidermal stem suspension with a specifiedconcentration, adding epidermal stem cells into atissue culture medium and carrying the cell viasubmerged culture.

 

Lu HLu HI, Wang X9/13/20074/2/2008
CN 101142897

A method for inducing and tissue culturing ofadventitious Pseudostellaria root, comprisingculturing root callus in an induction culturemedium and culturing the root in solid culturemedium and then in liquid culture mediumcontaining phytohormones.

 

Shanghai Jiaotong University (Shanghai)Gao X, Jia W,Zhao A11/8/20073/19/2008
CN 101138321

Virus-free tissue culture and rapid propagation of sugarcane, comprising preparing a culture medium, selecting explant, sterilization, induction cultureof callus, differentiation culture, rooting cultureand transplantation.

 

Zhejiang Academyof Agricultural Sciences(Zhejiang, China)Chen J, Jiang Y,Lu Y, Mu H, Xu G8/22/20073/12/2008
WO 2007139989

A method for preparing a sample such as a cellular sample, tissue sample, cell culture or cellularextract for analysis by mass spectroscopy, involving treating the sample with a fixative and analysis-enhancing material at temperature.

 

Brigham andWomen's Hospital (Boston), Brandeis University (Waltham, MA, USA)Agar JN, Agar NYR, Black PM5/26/200612/6/2007
 
Proteomics PDF Print E-mail
Monday, 23 March 2009 08:51
Patent numberDescriptionAssigneeInventorPriority application datePublication date

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://www.thomson.com/scientific).

WO 2008072209

A method for identifying and/or quantifying a target analyte present in sample by contacting the analyte with a probe molecule immobilized on a support and detecting the fluorescence signal induced in the spectral emission region of the fluorophore bound to the analyte.

 

Consiglio Nazionale delle Ricerche–Istitutonazionale per la Fisica della Materia (Genoa, Italy), Fondazione Istituto Italiano di Tecnologia (Genoa, Italy)Calabi F, Cingolani R, Pompa PP, Rinaldi R, Sabela S12/14/20068/21/2008
EP 1946843, US 20080184809

A method for monitoring and measuring the volume of liquid dispensed from a liquid-dispensing system, involving using an optical housing unit to measure the volume of dispensed liquid while the liquid maintains a cylindrical or quasi-cylindrical jet shape.

 

Allegro Research (Dublin)Franken C, Shvets I, Zawada TP, Shvets IV12/21/20067/23/2008, 8/7/2008
US 20080176229

A method of predicting the likelihood that a patient who is a candidate for treatment with an endothelial growth factor receptor (EGFR) inhibitor will respond to treatment, comprising determining the expression level of the transcript of STAT5B, or its expression product, in cancer cells obtained from the patient.

 

Agus D, Baker J, Cronin M, Shak SAgus D, Baker J, Cronin M, Shak S2/6/20047/24/2008
US 20080161206

A nominal scale factor determination method useful for reading biopolymeric (e.g., polypeptide and nucleic acid) arrays, involving collecting nominal scale factors for multiple dyes based on a recorded program; useful in genomics and proteomics.

 

Connell SD, Corson JF, Ghosh SConnell SD, Corson JF, Ghosh S12/23/20027/3/2008
US 20080156978

An interface apparatus for a differential mobility spectrometry (DMS) analyzer having electrodes with a gap to which ions are focused toward the median of the gap before and/or after at least one DMS analyzer.

 

Ibrahim YM, Shvartsberg AA, Smith RD, Tang KIbrahim YM, Shvartsberg AA, Smith RD, Tang K12/29/20067/3/2008
WO 2008079407

A method of comparing multiple mass spectra from different samples by using the daughter fragment mass spectrum to establish amino acid sequence data for identifying a peptide corresponding to a peak of interest in the single aligned mass spectrum.

 

Graves SWEsplin MS, Graves SW, Thulin CD12/26/20067/3/2008
WO 2008079269

A new set of descriptor genes combined into groups; useful for sub-categorizing breast cancers and identifying signals with bi- and multi-modal patterns across a set of high-throughput molecular data produced from biological samples.

 

Bugrim A, Nikolskaya T, Nikolsky YBugrim A, Nikolskaya T, Nikolsky Y12/19/20067/3/2008
WO 2008074861, FR 2910455

A method for forming nonaligned microcavities/microchannels, involving forming a shaft and/or trench in an amorphous or monocrystalline layer and annealing the layer in a hydrogenated atmosphere so as to transform the shaft and/or trench into two microcavities.

 

Commissariat à l'Énergie Atomique (Gif-sur-Yvette, France)Barbe J, Barbe JC, de Crecy F, Dornel E, Eymery J12/21/20066/26/2008, 6/27/2008
JP 2008122347

A method of immobilizing a protein on a conductive resin film having a light transmittance of predetermined wavelength; useful for preparing biosensors.

 

Sony (Tokyo)Negishi M, Shimura J, Tokita Y11/15/20065/29/2008
WO 2008058332

A method of diagnosing diabetes, complications associated with diabetes or a predisposition of a subject to develop diabetes by detecting a difference in the level of biomarkers in a biological sample to a statistically validated threshold.

 

Autogen Res. Pty. Ltd. (Brighton, Victoria, Australia)Blangero J, Collier GR, Curran JE, Jowett JBM, Moses EK, Shields KA, Walder KR11/14/20065/22/2008
WO 2008053150

A microfabricated device or its component that has a uniform nonwetting or nonabsorbing coating or surface modification formed at the surface by ionization or activation processing, to produce a surface energy value of less than 15 mNm-1.

 

P2I Ltd. (Abingdon, UK)Coulson S10/28/20065/8/2008
 
Sequencing PDF Print E-mail
Monday, 23 March 2009 08:50
Patent numberDescriptionAssigneeInventorPriority application datePublication date

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://www.thomson.com/scientific).

WO 2008112283

A method of predicting the responsiveness of a tumor to treatment for anti-androgen therapy for prostate cancer by determining the androgen responsiveness microRNA expression profile of the tumor and correlating it to the therapeutic treatment.

 

US Department of Health and Human Services (Washington, DC, USA)Kim CH, Munroe D, Soto J, Wu X3/12/20079/18/2008
US 20080199871

A method of determining the sequence of a nucleic acid polymer, comprising forming a complementary strand of the nucleic acid polymer and identifying a sequence of nucleotides in the nucleic acid polymer and/or in the complementary strand using a particle beam, where the nucleic acid polymer and/or the complementary strand is DNA or RNA.

 

ZS Genetics (Bryn Mawr, PA, USA)Glover WR7/14/20048/21/2008
CN 101246520

A protein compound identification method involving building a protein interaction un-digraph, inputting a group of protein interaction data and setting a permitted maximum din of a shortest distance between a protein peak and a threshold value tin, which is between 0 to 1. The weight of each edge in a network is calculated, where the edge weight is defined as number of a public neighbor peak of two peaks of the edge. A seed is selected, when a candidate seed queue does not empty, and the seed is expanded as an initial state of an identified protein compound.

 

Central South University (Changsha, China)Li M, Wang J3/18/20088/20/2008
WO 2008096375

A method for determining a susceptibility to prostate cancer comprising determining the presence or absence of polymorphic markers in a nucleic acid sample obtained from the individual.

 

Decode Genetics (Reykjavik, Iceland)Gudmundsson J, Sulem P2/7/20078/14/2008
CN 101234813

Biologically processing sewage by installing a micropore aeration plate on a barrier, fixing a dynamic film on the barrier and placing a sequencing batch biological film unit on the dynamic film.

 

Wuhan University of Science and Technology (Wuhan, China)Li Y, Yao M, Zhang Z11/22/20078/6/2008
JP 2008175793

A method of determining sugar chain arrangement using a mass spectrometer by cleaving sugar chains into fragments, subjecting them to mass spectrometry and comparing various sugar chain fragments spectra or calculated sugar chain arrangement data.

 

Lifix (Toyama, Japan)Anyoji H, Kanazawa M1/16/20077/31/2008
US 20080166773

A vector preparation comprising a double-stranded DNA molecule having 3'-termini, useful for preparing recombinant moleculeshaving only a single insert and for cloning PCR-amplified sequences.

 

Lucigen (Middleton, WI, USA)Godiska R, Hermanson S, Mead DA, Schoenfeld TW1/8/20077/10/2008
WO 2008041002

Pairwise sequencing of the first and second regions of a target double-stranded polynucleotide by carrying out an extension reaction, treating the first and second immobilized template strands and carrying out a second sequencing read.

 

Solexa (Saffron Walden, UK)Fashena S, Ost T, Rigatti R10/6/20064/10/2008
 
Protein Purification PDF Print E-mail
User Rating :  / 1
Monday, 23 March 2009 08:48
Patent numberDescriptionAssigneeInventorPriority application datePublication date

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://www.thomson.com/scientific).

WO 2008101667, US 20080249014

A method of obtaining highly purified hydrophobic protein comprising extracting the retentate by microdiafiltration using a buffer-solution containing a detergent and subjecting the filtrate to hydroxyapatite column chromatography.

 

Baxter Healthcare SA (Wallisellen, Switzerland), Baxter International (Deerfield, IL, USA), Mitterer A, Tauer CMitterer A, Tauer C2/22/20078/28/2008, 9/19/2008
US 20080221026

A method of manufacturing a nematode-extracted anticoagulant protein (NAP) drug substance comprising fermenting, recovering NAP from cells and cellular debris, and purifying the NAP drug substance away from contaminants.

 

Dendreon (Seattle)Lidell J, Mendoza CB, Moss D5/15/20039/11/2008
US 20080221309

A new biologically active recombinant antibody or biologically active recombinant antibody fragment, used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of proteins.

 

Pastorek J, Pastorekova S, Zavada JPastorek J, Pastorekova S, Zavada J3/11/19929/11/2008
WO 2008104606

Producing multimers of immunoglobulins in a cultured cell by co-expressing heavy chain, light chain and J chain and the endoplasmic reticulum Golgi intermediate compartment (ERGIC)-53 protein and purifying the cell culture supernatant.

 

Fondazione Centro San Raffaele del Monte Tabor (Milan)Anelli T, Sitia RM3/1/20079/4/2008
US 20080203351, CN 101241788

A magnetic nanocrystal, where the surface of the nanocrystal is bonded with a biocompatible macromolecule and an alkyl-containing molecule simultaneously; useful, for example, in biological applications such as DNA/RNA, protein and cell separation and purification.

 

Institute of Chemistry, The Chinese Academy of Sciences (Beijing), Gao M, Hu F, Liu S, Lu XGao M, Hu F, Liu S, Lu X1/15/20078/28/2008, 8/13/2008
WO 2008097870, US 20080206262

A method for increasing the effectiveness of antigen presentation comprising isolating and purifying a dendritic cell asialoglyco protein receptor (DC-ASGPR)-specific antibody or its fragment.

 

Baylor Research Institute (Dallas)Banchereau JF, Li D, Oh S, Zurawski G, Zurawski S2/2/20078/14/2008, 8/28/2008
WO 2008097829

Producing an active mammalian N-acetylglucosaminyltransferase I (GnT1) protein in bacteria comprising expressing the mammalian GnT1 protein in bacteria and solubilizing, refolding and purifying the soluble mammalian GnT1 protein.

 

Neose Technologies (Horsham, PA, USA)Johnson KF, Schwartz MF, Wu B2/2/20078/14/2008
WO 2008091740, US 20080193981

A method for purifying antibodies comprising adjusting the acidity or salt concentration of a mixture containing an antibody, adding a negatively or positively charged polyelectrolyte, and separating the protein-polyelectrolyte precipitate.

 

Genentech (So. San Francisco, CA, USA), Fahrner RL, Franklin J, McDonald P, Peram T, Sisodiya V, Victa CFahrner RL, Franklin J, McDonald P, Peram T, Sisodiya V, Victa C1/22/20077/31/2008, 8/14/2008
CN 101195651

A method of protein concentration/purification comprising using the difference between the charge properties of protein and amino acid ions under the action of an electric field and through gel crossover to move the protein from one container to another.

 

Guilin Medical College (Guangxi, China)Chen S, Chou X, Li S, Lu M, Shi W6/8/20076/11/2008
CN 101157059

A non-aperture amphoteric ion-exchange biological separating medium used for separating and purifying protein, enzyme and products.

 

Ningxia University (Yinchuan, China)Gong B8/15/20074/9/2008
EP 1876183, WO 2008003707

New factor VIII ligand peptide compounds useful for producing, labeling, detecting, diagnosing, monitoring, identifying, isolating, purifying, stabilizing and/or enhancing the activity of factor VIII or VIII-like protein and treat hemophilia A.

 

Technische Universitat Munchen (Munich)Hauser C, Kessler H, Khrenov A, Knoer S, Saenko E7/4/20061/9/2008, 1/10/2008
 
Antibody Fragments PDF Print E-mail
User Rating :  / 1
Monday, 23 March 2009 08:47
Patent numberDescriptionAssigneeInventorPriority application datePublication date

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://www.thomson.com/scientific).

JP 2008245601

A method of preparing a human single-chain variable gene fragment used for producing an antibody library by amplifying the human antibody heavy and light chain gene, digesting fragments and ligatingproducts, and amplifying the variable gene fragment.

 

Shizuoka-ken (Shizuoka, Japan)Akiyama Y, Maruyama K3/30/200710/16/2008
WO 2008121615

A new sterile, stable aqueous formulation comprising an antibody or fragment that specifically binds human interferon-alpha, or comprises a 13H5 anti-human interferon-alpha antibody; useful for treating an inflammatory disease.

 

MedImmune (Gaithersburg, MD, USA)Bishop S, Wolford JS3/30/200710/9/2008
US 20080248050

A new substance comprising an antibody molecule fragment exhibiting affinity for the target molecule; useful for inducing an immune response against a pathogen and for treating a patient infected with aparticular pathogen.

 

UChicago Argonne LLC (Chicago)Stevens FJ6/30/200610/9/2008
WO 2008118356

A new CD154 binding protein and related antibody useful for diagnosing and treating a human condition, disorder or disease mediated in whole or in part by CD40 signaling (e.g., immune, autoimmune orinflammatory response).

 

Biogen Idec (Cambridge, MA, USA), UCB Pharma (Brussels)Adams R, Brown DT, Burkly LC, Ferrant-Orgettas JL, Garber EA, Hsu Y, Popplewell AG, Robinson MK, Shock A, Su L, Taylor FR, Tyson KL3/22/200710/2/2008
CN 101270163

A new single-chain fragment antibody-polypeptide fusion protein, where the single chain fragmentantibody is Her2-scFv; useful as an anti-cancersiRNA drug carrier.

 

Sun Yat-Sen University (Guangzhou, China)Song E, Yao Y, Zhu P4/22/20089/24/2008
WO 2008107260

A new antibody fragment dimer where the antibody fragments are coupled at their C termini of theheavy chain polypeptides; useful for preparingpharmaceutical compositions for treating diseasesor disorders.

 

Novo Nordisk (Bagsvaerd, Denmark)Kjargaard K, Peschke B3/5/20079/12/2008
US 20080221309

A new biologically active recombinant antibody orbiologically active recombinant antibody fragment, used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MNproteins/polypeptides.

 

Pastorek J, Pastorekova S, Zavada JPastorek J, Pastorekova S, Zavada J3/11/19929/11/2008
US 20080213224, WO 2008105740

A method for identifying and selecting human scFv antibody fragments with specificity for BabA proteinby isolating RNA isolated from peripheral bloodlymphocytes of patients with inhibition-positive serato construct a phage display scFv library.

 

Boren T, Hammarström LBoren T, Hammarström L3/1/20079/4/2008
WO 2008088983

New pegylated Abeta antibody fragment, useful for treating or preventing a condition selected from Alzheimer's disease, Down syndrome, stroke, brain hemorrhage or general mental debilitation.

 

Eli Lilly & Co. (Indianapolis, IN, USA)Bales KR, Bumol TF, Chow C, Demattos RB, Hansen RJ, Kuchobhotla U, Lu J, McDonnell PC1/18/20077/24/2008
WO 2008071009

New ligand containing block copolymers usefulfor attaching a variety of targeting moieties (e.g., antibodies, peptides, lipids, oligonucleotides, antibody fragments, sugars and peptides).

 

University of Alberta (Edmonton, Alberta, Canada)Lavasanifar A, Xiong X12/15/20066/19/2008
 
Gene Expression PDF Print E-mail
Monday, 23 March 2009 08:44
Patent #SubjectAssignee(s)Inventor(s)Priority application datePublication date

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://www.thomson.com/scientific).

WO 2007034784

A connective tissue growth factor (CTGF) gene expression inhibitor comprising pyrrole imidazole polyamide having N-methyl pyrrole, N-methyl imidazole and gamma-aminobutryic acid units; useful for treating CTGF-associated disease.

 

Gentier Biosystems (Tokyo), Nihon University (Tokyo)Fukuda N, Sugiyama H, Ueno T9/20/20053/29/2007
WO 2007035950

A method of screening a library of RNA interference agents to identify an RNA interference agent or a cocktail of RNA interference agents that can inhibit expression of a first target gene, involving contacting the RNA interference agent or cocktail of RNA interference agents with cells organized in a matrix and detecting a change in expression of the first target gene in the cells or a change in the cells' phenotype.

 

B-Bridge International (Mountain View, CA, USA)Eguchi Y, Mizutani T, Shibamoto S9/23/20053/29/2007
US 20070036771

A method of regulating gene expression comprising introducing to gene depositories recombinant virus comprising an expression cassette including the regulatable transcription control element operably linked to an open reading frame of interest.

 

Cardiac Pacemakers (Minneapolis, MN, USA)Girouard SD, Heil RW, Qu J, Ross J, Sih HJ, Wagner DO8/12/20052/15/2007
US 20070031356

A method of screening for a compound that modulates an effect of UV irradiation by comparing the gene expression profiles of the cell contacted with thecompound before UV irradiation with those of control cells.

 

Buchwald HP, Goralczyk R, Hunziker W, Neeb M, Riss G, Seifert N, Steiner G, Wertz KBuchwald HP, Goralczyk R, Hunziker W, Neeb M, Riss G, Seifert N, Steiner G, Wertz K6/30/20062/8/2007
WO 2007045681, EP 1777291

A method for recovering RNA from a formalin-fixed, paraffin-embedded biological tissue sample for studying gene expression in tumor tissues, involving de-paraffinizing the sample, contacting with a solution containing proteinase K, heating and adding proteinase K.

 

Fundacion para la Investigacion Clinica y Molecular del Cancer de Pulmon (Barcelona, Spain)Rosell Costa RC,Taron Roca MC10/20/200510/19/2006, 10/20/2005
WO 2007047706

A method for inducing expression of a target protein comprising contacting the host cell with an agent, which suppresses the nonsense mutation. This gene regulation method does not rely on the control of transcription; useful in the study of gene expression.

 

Children's Hospital Medical Center (Boston, MA, USA)Mulligan R, Murphy GJ10/17/200510/17/2006
CN 1844387

An antisense oligonucleotide structure inhibiting expression of SIRT1 and used for treating lung, hepatic and pancreatic cancers.

 

Institute of Radiation Medicine (Beijing, PRC)Bo X, Lin R, Lou S, Sun D, Wang S4/26/200610/11/2006
WO 2007039454

A method of silencing or attenuating expression of a target gene for conferring in plants a trait, e.g., disease resistance by introducing or expressing into the plant a chimeric ribonucleotide sequence comprising a modified ta-siRNA sequence.

 

BASF Plant Science (Ludwigshafen, Germany)McMillan J, Ren P, Song H, Wang Y9/20/20059/20/2006
US 20070089203

A new stress-responsive promoter polynucleotide useful in conferring in a plant a desired trait, preferably increased dehydration stress tolerance or increased mechanical stress tolerance.

 

Bryant CJ, Elborough KM, Phillips JR, Puthigae S, Smith-Espinoza CJ, South CRBryant CJ, Elborough KM, Phillips JR, Puthigae S, Smith-Espinoza CJ, South CR8/9/20058/8/2006
WO 2007019062

A new isolated and purified zinc-finger polypeptide comprising a nucleotide binding region of 5 to 10 amino acid residues; useful as a gene expression regulator for treating cancer, for example.

 

Scripps Research Institute (La Jolla, CA, USA)Barbas CF, Dreier B8/11/20057/26/2006
 
RNA Interference PDF Print E-mail
Monday, 23 March 2009 08:41
Patent numberDescriptionAssigneeInventorPriority application datePublication date

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://www.thomson.com/scientific).

US 20090013433A transgenic plant comprising a brassinosteroid receptor BRI1 kinase inhibitor 1 (BKI1)-type polypeptide or modulator of bki1-type gene expression; useful for displaying modulated brassinosteroid response and plant phenotype. The modulator in the transgenic plant is an RNA interference or antisense molecule that inhibits translation of an mRNA that encodes a BKI1-type polypeptide.Salk Institute for Biological Sciences (La Jolla, CA, USA)Chory J, Wang X1/10/20071/8/2009
WO 2009002440A nucleic acid molecule that downregulates expression of an epidermal growth factor receptor (EGFR) gene via RNA interference; useful for preparing a composition for treating or preventing EGFR-expressing cancer.Liu Y, Xie FY, Yang XLiu Y, Xie FY, Yang X6/22/200712/31/2008
WO 2008155918A method of promoting or inhibiting activity of hypoxia-inducible factor-1alpha (HIF-1alpha), involving increasing or reducing the interaction of intracellular inhibitor of factor inhibiting HIF-1 (iFIH) protein and factor inhibiting HIF-1 (FIH-1) protein, or increasing or reducing the interaction of intracellular membrane type 1–matrix metalloproteinase–cytoplasmic tail binding protein (MT1-MMP-CP) and FIH-1 protein. The interaction of iFIH-1 and FIH-1 protein is reduced by decreasing the expression of iFIH-1 protein by RNA interference.University of Tokyo (Tokyo)Sakamoto T, Seiki M6/20/200712/24/2008
US 20080311081, WO 2008156702, WO 2008156661An invasive bacterium comprising small interfering RNA that interferes with the mRNA of human papilloma virus (HPV) oncogenes; useful for treating or preventing a viral disease or disorder—e.g., HPV infection.Cequent Pharmaceuticals (Cambridge, MA, USA); Fruehauf J, Laroux FS, Sauer NJ, Vaze MB, Beth Israel Deaconess Medical Center (Boston)Fruehauf J, Laroux FS, Sauer NJ, Vaze MB, Li C6/15/200712/18/2008, 12/24/2008, 12/24/2008
WO 2008152131A new RNA interference agent comprising sense strand; useful for treating a human subject afflicted with cystic fibrosis or Liddle syndrome, and for treating and/or preventing hypertension and/or renal insufficiency in a human subject.Novartis (Basel, Switzerland)Danahay HL, Geick A, Hickman E, Tan P, van Heeke G, Vornlocher H6/15/200712/18/2008
JP 2008301812A kit comprising a vector containing a promoter derived from phage used for producing double-stranded RNA having an RNA interference effect in lactic acid bacteria. The lactic acid bacteria are useful in compositions for killing intestinal parasites and treating enteric diseases—e.g., Caenorhabditis and Ascaris.Okayama University (Japan)Otsuki T, Shishido M5/10/200712/18/2008
WO 2008148304, CN 101314775An HIV-targeted RNA interference target sequence; useful for treating HIV infection.Xiamen University (Xiamen, China); Yang Sheng Tang Co. (Haikou, China)Cheng T, Miao J, Xia N, Zhang J, Zhang T, Zhang Y5/31/200712/11/2008, 12/3/2008
CN 101246169A diagnostic reagent for oral squamous cell carcinoma comprising a reagent capable of detecting the expression level of RACK1 protein and its mRNA content; useful for preparing a kit or biochip for oral mucosa carcinoma. The drug comprises an RNA interference molecule of RACK1 protein.University of Sichuan (China)Ceng X, Chen Q, Huang C, Wang Z5/23/20078/20/2008
JP 2008167739A novel modified double-stranded RNA having RNA interference activity, comprising sense strand RNA having a complementary base sequence to a target gene and an antisense strand RNA for suppressing expression of the target gene.National Institute of Advanced Industrial Science and Technology (Tokyo)Bakalova R, Kubo T, Oba H, Zhelev Z6/14/20067/24/2008
 
<< Start < Prev 1 2 Next > End >>

Page 2 of 2